新型冠状病毒肺炎患者的血栓风险及治疗进展

Thrombotic Risk and Therapeutic Advances in Patients with COVID-19

新型冠状病毒肺炎(COVID-19)是一种呼吸道疾病,其主要通过呼吸道在人与人间传播,由SARS-CoV-2病毒引起。COVID-19经过传播导致疫病在全世界范围内大流行,快速扩张,对人类的健康及全球的经济发展造成了不可估量的危害。目前研究证据表明,COVID-19已发生多次变异,传染性极高,病毒载量增加,COVID-19大流行大大增加了许多患者发生静脉和动脉血栓栓塞事件的风险,因此,全面认识COVID-19血栓风险及治疗进展对新型冠状病毒感染患者的预后极其重要。本文简要叙述COVID-19血栓形成机制,并对血栓危险因素及治疗进展作一系统综述。Novel coronavirus pneumonia (COVID-19) is a respiratory disease that spreads from person to person primarily through the respiratory tract and is caused by the SARS-CoV-2 virus. The spread of COVID-19 has resulted in a global pandemic and rapid expansion of the epidemic, posing an incalculable risk to human health and global economic development. Current research suggests that COVID-19 has undergone multiple mutations, is highly infectious, has an elevated viral load, and that the COVID-19 pandemic has greatly increased the risk of venous and arterial thromboembolic events in many patients;therefore, a comprehensive understanding of the risk of COVID-19 thrombosis and therapeutic advances are extremely important for the prognosis of patients with novel coronavirus infections. This article briefly describes the mechanism of COVID-19 thrombosis and provides a systematic review of thrombotic risk factors and therapeutic advances.